Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or “on-target/off-tumor” toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumorassociated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal—curing cancer with high safety, high efficacy, and low cost.

Keywords

chimeric antigen receptors / cancer adoptive immunotherapy / T lymphocytes / gene therapy / gene editing

References

[1] AhmedN, BrawleyVS, HegdeM, RobertsonC, GhaziA, GerkenC, LiuE, DakhovaO, AshooriA, CorderA (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma.J Clin Oncol33:1688–1696

[2] Alvarez-RuedaN, DesselleA, CochonneauD, ChaumetteT, ClemenceauB, LeprieurS, BougrasG, SupiotS, MussiniJM, BarbetJ (2011) A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.PloS one6:e25220

[3] AnkriC, ShamalovK, Horovitz-FriedM, MauerS, CohenCJ (2013) Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.J Immunol191:4121–4129

[4] BarrettDM, TeacheyDT, GruppSA (2014) Toxicity management for patients receiving novel T-cell engaging therapies.Curr Opin Pediatr26:43–49

[5] BeaneJD, LeeG, ZhengZ, MendelM, Abate-DagaD, BharathanM, BlackM, GandhiN, YuZ, ChandranS (2015) Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma.Mol Ther23:1380–1390

[6] BeattyGL, HaasAR, MausMV, TorigianDA, SoulenMC, PlesaG, ChewA, ZhaoY, LevineBL, AlbeldaSM (2014) Mesothelinspecific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res2:112–120

[7] BerdienB, MockU, AtanackovicD, FehseB (2014) TALENmediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer.Gene Ther21:539–548

[8] BoniniC, FerrariG, VerzelettiS, ServidaP, ZapponeE, RuggieriL, PonzoniM, RossiniS, MavilioF, TraversariC(1997) HSVTK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.Science276:1719–1724

[9] BrownCE, AlizadehD, StarrR, WengL, WagnerJR, NaranjoA, OstbergJR, BlanchardMS, KilpatrickJ, SimpsonJ (2016) Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.N Engl J Med375:2561–2569

[10] CarpenitoC, MiloneMC, HassanR, SimonetJC, LakhalM, SuhoskiMM, Varela-RohenaA, HainesKM, HeitjanDF,AlbeldaSM (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.Proc Natl Acad Sci USA106:3360–3365

[11] CarpenterRO, EvbuomwanMO, PittalugaS, RoseJJ, RaffeldM, YangS,GressREHakimFT, KochenderferJN (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.Clin Cancer Res19:2048–2060

[12] CarusoHG, HurtonLV, NajjarA, RushworthD, AngS, OlivaresS, MiT, SwitzerK, SinghH, HulsH (2015) Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity.Cancer Res75:3505–3518

[13] CherkasskyL, MorelloA, Villena-VargasJ, FengY, DimitrovDS, JonesDR, SadelainM, AdusumilliPS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.J Clin Investig126:3130–3144

[14] ChinnasamyD, YuZ, TheoretMR, ZhaoY, ShrimaliRK, MorganRA, FeldmanSA, RestifoNP, RosenbergSA (2010) Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.J Clin Investig120:3953–3968

[15] ChmielewskiM, AbkenH (2015) TRUCKs: the fourth generation of CARs.Expert Opin Biol Ther15:1145–1154

[16] ChmielewskiM, HombachA, HeuserC, AdamsGP, AbkenH (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.J Immunol173:7647–7653

[17] ChmielewskiM, HombachAA, AbkenH (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.Immunol Rev257:83–90

[18] CiceriF, BoniniC, StanghelliniMT, BondanzaA, TraversariC, SalomoniM, TurchettoL, ColombiS, BernardiM, PeccatoriJ (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.Lancet Oncol10:489–500

[19] CongL, RanFA, CoxD, LinS, BarrettoR, HabibN, HsuPD, WuX, JiangW, MarraffiniLA (2013) Multiplex genome engineering using CRISPR/Cas systems.Science339:819–823

[20] CraddockJA, LuA, BearA, PuleM, BrennerMK, RooneyCM, FosterAE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.J Immunother33:780–788

[21] CurranMA, MontalvoW, YagitaH, AllisonJP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci USA107:4275–4280

[22] EshharZ, WaksT, GrossG, SchindlerDG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proc Natl Acad Sci USA90:720–724

[23] EyquemJ, Mansilla-SotoJ, GiavridisT, van der StegenSJ, HamiehM, CunananKM, OdakA, GonenM, SadelainM (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Nature543:113–117

[24] FaitschukE, HombachAA, FrenzelLP, WendtnerCM, AbkenH (2016) Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells.Blood128:1711–1722

[25] FengK, GuoY, DaiH, WangY, LiX, JiaH, HanW (2016) Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.Sci China Life Sci59:468–479

[26] FinneyHM, LawsonAD, BebbingtonCR, WeirAN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.J Immunol161:2791–2797

[27] FitzGeraldDJ, WayneAS, KreitmanRJ, PastanI (2011) Treatment of hematologic malignancies with immunotoxins and antibodydrug conjugates.Cancer Res71:6300–6309

[28] GruppSA, KalosM, BarrettD, AplencR, PorterDL, RheingoldSR, TeacheyDT, ChewA, HauckB, WrightJF (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N Engl J Med368:1509–1518

[29] GubinMM, ZhangX, SchusterH, CaronE, WardJP, NoguchiT, IvanovaY, HundalJ, ArthurCD, KrebberWJ (2014) Checkpoint blockade cancer immunotherapy targets tumourspecific mutant antigens.Nature515:577–581

[30] HasoW, LeeDW, ShahNN, Stetler-StevensonM, YuanCM, PastanIH, DimitrovDS, MorganRA, FitzGeraldDJ, BarrettDM (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.Blood121:1165–1174

[31] HongH, StastnyM, BrownC, ChangWC, OstbergJR, FormanSJ, JensenMC (2014) Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.J Immunother37:93–104

[32] HoyosV, SavoldoB, QuintarelliC, MahendravadaA, ZhangM, VeraJ, HeslopHE, RooneyCM, BrennerMK, DottiG (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.Leukemia24:1160–1170

[33] HudecekM, SchmittTM, BaskarS, Lupo-StanghelliniMT, NishidaT, YamamotoTN, BleakleyM, TurtleCJ, ChangWC, GreismanHA (2010) The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Blood116:4532–4541

[34] HudecekM, Lupo-StanghelliniMT, KosasihPL, SommermeyerD, JensenMC, RaderC, RiddellSR (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor Tcells.Clin Cancer Res19:3153–3164

[35] JohnsonLA, SchollerJ, OhkuriT, KosakaA, PatelPR, McGettiganSE, NaceAK, DentchevT, ThekkatP, LoewA (2015) Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.Sci Transl Med7:275ra222

[36] KershawMH, WestwoodJA, ParkerLL, WangG, EshharZ, MavroukakisSA, WhiteDE, WunderlichJR, CanevariS, Rogers-FreezerL (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clinl Cancer Res12:6106–6115

[37] KlossCC, CondominesM, CartellieriM, BachmannM, SadelainM (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.Nat Biotechnol31:71–75

[38] LamersCH, SleijferS, VultoAG, KruitWH, KliffenM, DebetsR, GratamaJW, StoterG, OosterwijkE (2006a) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.J Clin Oncol24:e20–e22

[39] LamersCH, van ElzakkerP, LangeveldSC, SleijferS, GratamaJW (2006b) Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient’s T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.Cytotherapy8:542–553

[40] LanitisE, PoussinM, KlattenhoffAW, SongD, SandaltzopoulosR, JuneCH, PowellDJ Jr (2013) Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.Cancer Immunol Res1:43–53

[41] LinetteGP, StadtmauerEA, MausMV, RapoportAP, LevineBL, EmeryL, LitzkyL, BaggA, CarrenoBM, CiminoPJ (2013) Cardiovascular toxicity and titin cross-reactivity of affinity enhanced Tcells in myeloma and melanoma.Blood122:863–871

[42] LiuX, JiangS, FangC, YangS, OlalereD, PequignotEC, CogdillAP, LiN, RamonesM, GrandaB (2015) Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice.Cancer Res75:3596–3607

[43] LiuX, RanganathanR, JiangS, FangC, SunJ, KimS, NewickK, LoA, JuneCH, ZhaoY (2016a) A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res76:1578–1590

[44] LiuX, ZhangY, ChengC, ChengAW, ZhangX, LiN, XiaC, WeiX, LiuX, WangH(2016b) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.Cell Res27:154–157

[45] LouisCU, SavoldoB, DottiG, PuleM, YvonE, MyersGD, RossigC, RussellHV, DioufO, LiuE (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.Blood118:6050–6056

[46] LuYC, RobbinsPF (2016) Cancer immunotherapy targeting neoantigens.Semin Immunol28:22–27

[47] MacLeodDT, AntonyJ, MartinAJ, MoserRJ, HekeleA, WetzelKJ, BrownAE, TriggianoMA, HuxJA, PhamCD (2017) Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells.Mol Ther25:949–961

[48] MaherJ, BrentjensRJ, GunsetG, RiviereI, SadelainM(2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.Nat Biotechnol20:70–75

[49] MardirosA, Dos SantosC, McDonaldT, BrownCE, WangX, BuddeLE, HoffmanL, AguilarB, ChangWC, BretzlaffW (2013) T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Blood122:3138–3148

[50] MaudeSL, FreyN, ShawPA, AplencR, BarrettDM, BuninNJ, ChewA, GonzalezVE, ZhengZ, LaceySF (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med371:1507–1517

[51] MausMV, HaasAR, BeattyGL, AlbeldaSM, LevineBL, LiuX, ZhaoY, KalosM, JuneCH (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Cancer Immunol Res1:26–31

[52] MorganRA, YangJC, KitanoM, DudleyME, LaurencotCM, RosenbergSA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther18:843–851

[53] MorganRA, ChinnasamyN, Abate-DagaD, GrosA, RobbinsPF, ZhengZ, DudleyME, FeldmanSA, YangJC, SherryRM (2013) Cancer regression and neurological toxicity following Anti-MAGE-A3 TCR gene therapy.J Immunother36:133–151

[54] NewickK, O’BrienS, SunJ, KapoorV, MaceykoS, LoA, PureE, MoonE, AlbeldaSM (2016) Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization.Cancer Immunol Res4:541–551

[55] OliveiraG, GrecoR, Lupo-StanghelliniMT, VagoL, BoniniC (2012) Use of TK-cells in haploidentical hematopoietic stem cell transplantation.Curr Opin Hematol19:427–433

[56] OrenR, Hod-MarcoM, Haus-CohenM, ThomasS, BlatD, DuvshaniN, DenkbergG, ElbazY, BenchetritF, EshharZ (2014) Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.J Immunol193:5733–5743

[57] ParkJR, DigiustoDL, SlovakM, WrightC, NaranjoA, WagnerJ, MeechoovetHB, BautistaC, ChangWC, OstbergJR(2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.Mol Ther15:825–833

[58] ParkhurstMR, YangJC, LanganRC, DudleyME, NathanDA, FeldmanSA, DavisJL, MorganRA, MerinoMJ, SherryRM (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Mol Ther19:620–626

[59] PhilipB, KokalakiE, MekkaouiL, ThomasS, StraathofK, FlutterB, MarinV, MarafiotiT, ChakravertyR, LinchD (2014) A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.Blood124:1277–1287

[60] PorterDL, LevineBL, KalosM, BaggA, JuneCH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med365:725–733

[61] PorterDL, HwangWT, FreyNV, LaceySF, ShawPA, LorenAW, BaggA, MarcucciKT, ShenA, GonzalezV(2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.Sci Transl Med7:303ra139

[62] PoseyAD Jr, SchwabRD, BoesteanuAC, SteentoftC, MandelU, EngelsB, StoneJD, MadsenTD, SchreiberK, HainesKM (2016) Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma.Immunity44:1444–1454

[63] ProsserME, BrownCE, ShamiAF, FormanSJ, JensenMC (2012) Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.Mol Immunol51:263–272

[64] ProvasiE, GenoveseP, LombardoA, MagnaniZ, LiuPQ, ReikA, ChuV, PaschonDE, ZhangL, KuballJ (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.Nat Med18:807–815

[65] QasimW, ZhanH, SamarasingheS, AdamsS, AmroliaP, StaffordS, ButlerK, RivatC, WrightG, SomanaK (2017) Molecular remission of infant B-ALL after infusion of universal TALEN geneedited CAR T cells.Sci Transl Med9:eaaj2013

[66] RafiqS, PurdonTJ, DaniyanAF, KoneruM, DaoT, LiuC, ScheinbergDA, BrentjensRJ (2016) Optimized T-cell receptormimic (TCRm) chimeric antigen receptor T-cells directed towards the intracellular Wilms Tumor 1 antigen.Leukemia.

[67] ReiterY, Di CarloA, FuggerL, EngbergJ, PastanI (1997) Peptidespecific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.Proc Natl Acad Sci USA94:4631–4636

[68] RenJ, LiuX, FangC, JiangS, JuneCH, ZhaoY (2016) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition.Clin Cancer Res.

[69] RobbinsPF, LuYC, El-GamilM, LiYF, GrossC, GartnerJ, LinJC, TeerJK, CliftenP, TycksenE(2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.Nat Med19:747–752

[70] RobertC, LongGV, BradyB, DutriauxC, MaioM, MortierL, HasselJC, RutkowskiP, McNeilC, Kalinka-WarzochaE (2015) Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med372:320–330

[71] RoybalKT, RuppLJ, MorsutL, WalkerWJ, McNallyKA, ParkJS, LimWA (2016a) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits.Cell164:770–779

[72] RoybalKT, WilliamsJZ, MorsutL, RuppLJ, KolinkoI, ChoeJH, WalkerWJ, McNallyKA, LimWA (2016b) Engineering Tcells with customized therapeutic response programs using synthetic notch receptors.Cell167(419–432):e416

[73] SakemuraR, TerakuraS, WatanabeK, JulamaneeJ, TakagiE, MiyaoK, KoyamaD, GotoT, HanajiriR, NishidaT (2016) A Tet-On inducible system for controlling CD19-Chimeric antigen receptor expression upon drug administration.Cancer Immunol Res4:658–668

[74] SakuishiK, ApetohL, SullivanJM, BlazarBR, KuchrooVK, AndersonAC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med207:2187–2194

[75] SampsonJH, ChoiBD, Sanchez-PerezL, SuryadevaraCM, SnyderDJ, FloresCT, SchmittlingRJ, NairSK, ReapEA, NorbergPK (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.Clin Cancer Res20:972–984

[76] SchubertML, HuckelhovenA, HoffmannJM, SchmittA, WuchterP, SellnerL, HofmannS, HoAD, DregerP, SchmittM (2016) Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation.Hum Gene Ther27(10):758–771

[77] SchumacherTN, SchreiberRD (2015) Neoantigens in cancer immunotherapy.Science348:69–74

[78] SinghJA, BegS, Lopez-OlivoMA (2011) Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.J Rheumatol38:10–20

[79] SinghN, LiuX, HulittJ, JiangS, JuneCH, GruppSA, BarrettDM, ZhaoY (2014) Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.Cancer Immunol Res2:1059–1070

[80] SmithMR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.Oncogene22:7359–7368

[81] SuzukiM, CheungNK (2015) Disialoganglioside GD2 as a therapeutic target for human diseases.Expert Opin Ther Targets19:349–362

[82] TaubeJM, KleinA, BrahmerJR, XuH, PanX, KimJH, ChenL, PardollDM, TopalianSL, AndersRA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res20:5064–5074

[83] TillBG, JensenMC, WangJ, ChenEY, WoodBL, GreismanHA, QianX, JamesSE, RaubitschekA, FormanSJ (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood112:2261–2271

[84] TillBG, JensenMC, WangJ, QianX, GopalAK, MaloneyDG, LindgrenCG, LinY, PagelJM, BuddeLE (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Blood119:3940–3950

[85] TopalianSL, SznolM, McDermottDF, KlugerHM, CarvajalRD, SharfmanWH, BrahmerJR, LawrenceDP, AtkinsMB, PowderlyJD (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol32:1020–1030

[86] TorikaiH, ReikA, SoldnerF, WarrenEH, YuenC, ZhouY, CrosslandDL, HulsH, LittmanN, ZhangZ (2013) Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.Blood122:1341–1349

[87] TranE, TurcotteS, GrosA, RobbinsPF, LuYC, DudleyME, WunderlichJR, SomervilleRP, HoganK, HinrichsCS (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.Science344:641–645

[88] TuguesS, BurkhardSH, OhsI, VrohlingsM, NussbaumK, Vom BergJ, KuligP, BecherB(2015) New insights into IL-12-mediated tumor suppression.Cell Death Differ22:237–246

[89] ValtonJ, GuyotV, MarechalA, FilholJM, JuilleratA, DuclertA, DuchateauP, PoirotL (2015) A Multidrug-resistant Engineered CAR T cell for allogeneic combination immunotherapy.Mol Ther23:1507–1518

[90] VeraJ, SavoldoB, VigourouxS, BiagiE, PuleM, RossigC, WuJ, HeslopHE, RooneyCM, BrennerMK (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.Blood108:3890–3897

[91] WangX, ChangWC, WongCW, ColcherD, ShermanM, OstbergJR, FormanSJ, RiddellSR, JensenMC (2011) A transgeneencoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.Blood118:1255–1263

[92] WatanabeK, TerakuraS, MartensAC, van MeertenT, UchiyamaS, ImaiM, SakemuraR, GotoT, HanajiriR, ImahashiN (2015) Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells.J Immunol194:911–920

[93] WilkieS, van SchalkwykMC, HobbsS, DaviesDM, van der StegenSJ, PereiraAC, BurbridgeSE, BoxC, EcclesSA, MaherJ (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.J Clin Immunol32:1059–1070

[94] WolchokJD, HodiFS, WeberJS, AllisonJP, UrbaWJ, RobertC, O’DaySJ, HoosA, HumphreyR, BermanDM (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.Ann N Y Acad Sci1291:1–13

[95] WuCY, RoybalKT, PuchnerEM, OnufferJ, LimWA (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.Science350:aab4077

[96] YarchoanM, JohnsonBA III, LutzER, LaheruDA, JaffeeEM (2017) Targeting neoantigens to augment antitumour immunity.Nat Rev Cancer17:209–222

[97] ZahE, LinMY, Silva-BenedictA, JensenMC, ChenYY (2016) Tcells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells.Cancer Immunol Res4:498–508

[98] ZhangL, KerkarSP, YuZ, ZhengZ, YangS, RestifoNP, RosenbergSA, MorganRA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Mol Ther19:751–759

[99] ZhangL, MorganRA, BeaneJD, ZhengZ, DudleyME, KassimSH, NahviAV, NgoLT, SherryRM, PhanGQ (2015) Tumorinfiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.Clin Cancer Res21:2278–2288

[100] ZhangW-Y, WangY, GuoY-L, DaiH-R, YangQ-M, ZhangY-J, ZhangY, ChenM-X, WangC-M, FengK-C (2016) Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.Signal Transduct Target Ther1:16002

[101] ZhaoY, ZhengZ, CohenCJ, GattinoniL, PalmerDC, RestifoNP, RosenbergSA, MorganRA (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.Mol Ther13:151–159

[102] ZhaoY, WangQJ, YangS, KochenderferJN, ZhengZ, ZhongX, SadelainM, EshharZ, RosenbergSA, MorganRA (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.J Immunol183:5563–5574

[103] ZhaoY, MoonE, CarpenitoC, PaulosCM, LiuX, BrennanAL, ChewA, CarrollRG, SchollerJ, LevineBL (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.Cancer Res70:9053–9061

[104] ZhuX, PrasadS, GaedickeS, HettichM, FiratE, NiedermannG (2015) Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.Oncotarget6:171–184

RIGHTS & PERMISSIONS

The Author(s) 2017. This article is an open access publication